Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia
- 1 January 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (1) , 375
- https://doi.org/10.1182/blood-2002-08-2557
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phaseBlood, 2000
- Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometryBlood, 2000
- Telomere Fluorescence Measurements in Granulocytes and T Lymphocyte Subsets Point to a High Turnover of Hematopoietic Stem Cells and Memory T Cells in Early ChildhoodThe Journal of Experimental Medicine, 1999
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996
- Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reactionBlood, 1996
- Structure and function of telomeresNature, 1991